Detection of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in post-mortem blood specimens using infectious disease assays licensed for cadaveric donor screening.
TRANSPLANT INFECTIOUS DISEASE(2018)
摘要
BackgroundEvaluation of assay performance on postmortem blood specimens (obtained after cessation of the heartbeat) presents unique scientific and regulatory challenges. In the United States, assay performance is evaluated in part by spiking postmortem specimens. MethodsFifty-four specimens obtained from decedents known to be infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV), including some coinfections, were tested for each virus using Food and Drug Administration (FDA)-licensed donor screening tests for nucleic acid, antibody, and antigen. ResultsFor each disease, >95% of subjects who were reported to have an infection at the time of death had a positive test result on at least one of the donor screening assays for that infection. ConclusionLicensed donor screening tests were positive on postmortem specimens obtained within 24hours of death from individuals dying with HIV, HCV, and/or HBV, and were able to detect presence of the virus. The use of multiple tests (including antibody and direct viral detection methods) is necessary to adequately evaluate donors.
更多查看译文
关键词
antibody,cadaveric,infectious disease testing,NAT,postmortem,tissue
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要